comparemela.com
Home
Live Updates
Ascletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHB : comparemela.com
Ascletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHB
/PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces late-breaking abstract poster presentation of interim results from Phase IIb...
Related Keywords
China ,
Shaoxing ,
Zhejiang ,
Germany ,
Italy ,
United Kingdom ,
Japan ,
France ,
Hangzhou ,
Hong Kong ,
Spain ,
United States ,
American ,
Chinese ,
Jinzij Wu ,
,
Ascletis Pharma Inc ,
Hong Kong Stock Exchange ,
Prnewswire Ascletis Pharma Inc ,
American Association ,
Liver Diseases ,
Breaking Abstract Poster Presentation ,
Chronic Hepatitisb Patients After ,
Week Treatment ,
Subcutaneously Administered ,
Interim Results ,
Thyroid Hormone Receptor ,
Showed Little Drug Interaction ,
Significant Lipid Reduction ,
Comparable Pharmacokinetic Profiles ,
Non Alcoholic Fatty Liver Disease ,
Two Phase ,
Chronic Hepatitisb Virus Infection ,
comparemela.com © 2020. All Rights Reserved.